{
    "nct_id": "NCT00141661",
    "title": "A Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multiple Dose, Multicenter Study in Subjects With Mild to Moderate Dementia of the Alzheimer's Type to Evaluate the Safety and Tolerability of Two 10-Week Dose Regimens of Orally-Administered PF-04494700",
    "status": "COMPLETED",
    "last_update_time": "2009-08-19",
    "description_brief": "A 10-week safety and tolerability study of a potential treatment for mild to moderate Alzheimer's disease.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "PF-04494700 (Azeliragon, also known as TTP488)"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The investigational agent is PF-04494700 (Azeliragon/TTP488), an orally administered inhibitor of the receptor for advanced glycation end products (RAGE) developed for Alzheimer disease; this identifies it as a small-molecule therapeutic rather than a biologic. \ue200cite\ue202turn0search3\ue202turn0search5\ue201",
        "Act: The study is a 10-week, double-blind, randomized, placebo-controlled Phase IIa multiple-dose safety/tolerability trial in mild\u2013moderate Alzheimer\u2019s disease, matching the title/description provided. \ue200cite\ue202turn0search3\ue202turn0search4\ue201",
        "Act (mechanism): PF-04494700 was developed to inhibit RAGE\u2013A\u03b2 interactions and related inflammatory/amyloid pathways \u2014 i.e., it targets Alzheimer\u2019s pathophysiology rather than acting as a symptomatic cognitive enhancer or an agent for neuropsychiatric symptoms. \ue200cite\ue202turn0search2\ue202turn0search3\ue201",
        "Reflect: Given the drug is a small-molecule RAGE inhibitor aimed at modulating AD-related pathology, the correct category is 'disease-targeted small molecule'. The brief 10-week pilot showed safety/tolerability but no consistent short-term cognitive effects, which is consistent with a disease-modifying (pathology-targeted) mechanism requiring longer follow-up. \ue200cite\ue202turn0search3\ue202turn0search0\ue201",
        "Sources / supporting trial records and papers: Phase IIa 10-week safety report and full-text trial description (PMC), PubMed abstract, Neurology publication on longer RAGE inhibitor trial, and ClinicalTrials entry for NCT00141661. \ue200cite\ue202turn0search3\ue202turn0search0\ue202turn0search2\ue202turn0search4\ue201"
    ],
    "agent_type": "F) Inflammation",
    "explanation_agent": [
        "Reason: The investigational agent is PF-04494700 (Azeliragon, TTP488), an orally available small-molecule antagonist of the receptor for advanced glycation end products (RAGE). RAGE is a cell-surface receptor that drives inflammatory signaling (NF-\u03baB and related pathways), and also binds A\u03b2 and mediates A\u03b2 transport \u2014 so the drug\u2019s mechanism is primarily to block RAGE-mediated inflammation and related downstream effects. \ue200cite\ue202turn0search2\ue202turn0search7\ue201",
        "Act: Extracted details from the trial description \u2014 drug PF-04494700 (Azeliragon/TTP488), disease-targeted small molecule, Phase IIa multiple-dose safety/tolerability study in mild\u2013moderate AD (10-week pilot and larger 18-month follow-ups). Mechanistically this compound was developed to inhibit RAGE\u2013A\u03b2 interactions and RAGE-driven inflammatory/oxidative pathways rather than being a symptomatic neurotransmitter modulator. \ue200cite\ue202turn0search2\ue202turn0search0\ue202turn0search7\ue201",
        "Reflect: Mapping to CADRO \u2014 RAGE is an inflammatory receptor whose blockade is intended to reduce neuroinflammation and downstream oxidative/toxic signaling. Although RAGE inhibition can also affect A\u03b2 transport/amyloid-related processes, the most specific CADRO match is F) Inflammation (primary biological focus = inflammatory signaling). An alternative reasonable mapping could be A) Amyloid beta (because of effects on A\u03b2\u2013RAGE interactions) or R) Multi-target (inflammation + amyloid), but F) Inflammation is the best single-category fit given the receptor\u2019s role and the drug\u2019s anti-inflammatory rationale. \ue200cite\ue202turn0search2\ue202turn0search7\ue201",
        "Web search results (sources used): 1) PubMed/Neurology report of the RAGE inhibitor clinical trial (PF\u201104494700) \u2014 trial outcomes and safety/tolerability details. \ue200cite\ue202turn0search0\ue202turn0search1\ue201 2) Alzforum summary page for Azeliragon (PF\u201104494700/TTP488) \u2014 mechanism as an oral RAGE antagonist, development history. \ue200cite\ue202turn0search2\ue201 3) PMC article on development and mechanism of azeliragon (RAGE biology, rationale for AD) \u2014 reviews RAGE\u2019s links to inflammation, oxidative stress, and A\u03b2 transport. \ue200cite\ue202turn0search7\ue201 4) Supporting reagent/product pages and preclinical summaries describing azeliragon as a RAGE inhibitor with anti\u2011inflammatory and anti\u2011amyloid effects. \ue200cite\ue202turn0search3\ue202turn0search4\ue201"
    ]
}